0VGI.L

TG Therapeutics, Inc.
LSEUSDEQUITY DELAYED
Last price
56.70
▲ 20.05 (54.71%)
MARKET ·

Price

1D H L Range Vol
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
Prev close
36.65
Day high
56.70
Day low
56.70
Volume
0
Market cap
P/E (TTM)
52W range
6.47 – 56.70

Unusual options activity

Account required
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
Free account required

Contracts trading at or above their open interest, ranked by notional and where the print landed.

Free account

5 more panels on 0VGI.L open with an account.

Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.

Insider net activity

6m · Form 4 rollup
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
Net transactions
0
Buys less sells
Sell : buy shares
Not enough filings
Insider-held shares
10.59M
Total on file

Insider transactions

Account required
DateInsiderAction SharesValueHeld
Aug 7, 26
CHARNEY LAURENCE NEIL
Director
STOCK 6.05K $0 Direct
Jan 29, 26
CHARNEY LAURENCE NEIL
Director
STOCK 43.20K $0 Direct
Jan 8, 26
POWER SEAN A
Chief Financial Officer
STOCK 90.00K $0 Direct
Jan 8, 26
WEISS MICHAEL S
Chief Executive Officer
STOCK 622.00K $0 Direct
Nov 24, 25
ECHELARD YANN
Director
SELL 5.00K $162.85K Direct
Nov 5, 25
WEISS MICHAEL S
Chief Executive Officer
STOCK 4.67M $0 Direct
Sep 11, 25
LONIAL SAGAR
Director
SELL 20.85K $672.27K Direct
Jun 13, 25
ECHELARD YANN
Director
SELL 10.00K $369.40K Direct
Jun 12, 25
HUME DANIEL
Director
STOCK 14.72K $0 Direct
Jun 12, 25
LONIAL SAGAR
Director
STOCK 14.72K $0 Direct
Jun 12, 25
CHARNEY LAURENCE NEIL
Director
STOCK 21.41K $0 Direct
Jun 12, 25
ECHELARD YANN
Director
STOCK 14.72K $0 Direct
Jun 12, 25
HOBERMAN KENNETH
Director
STOCK 14.72K $0 Direct
Mar 17, 25
HUME DANIEL
Director
STOCK 62.46K $0 Direct
What this is, and what it is not

These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.

A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.

This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.

Free account required

Officer and director trades in their own stock, straight from Form 4 filings.

Insider holders

7 reporting
NameRelationShares heldLatest
CHARNEY LAURENCE NEIL
Director 173.64K Stock Gift
ECHELARD YANN
Director 223.82K Sale
HOBERMAN KENNETH
Director 279.65K Stock Award(Grant)
HUME DANIEL
Director 192.75K Stock Award(Grant)
LONIAL SAGAR
Director 94.06K Sale
POWER SEAN A
Chief Financial Officer 798.11K Stock Award(Grant)
WEISS MICHAEL S
Chief Executive Officer 9.78M Stock Award(Grant)

Fundamentals

TTM · reported
Market cap
Enterprise value$8.24B
Revenue (TTM)$799.54M
Gross profit$658.60M
EBITDA$136.45M
Net income$441.49M
EPS (TTM)$-2.46
Free cash flow$59.13M
Total cash$552.25M
Total debt$754.44M
Book value / share$4.26
Shares outstanding76.83M
Float135.24M
Short % of float
Dividend yield
Beta (5Y)1.67

Valuation & profitability ratios

Account required
Trailing P/E
Forward P/E
PEG ratio
Price / sales
Price / book13.32
EV / revenue10.31
EV / EBITDA60.42
Gross margin82.37%
Operating margin9.02%
Profit margin55.22%
Return on equity100.28%
Return on assets7.28%
Debt / equity124.89
Current ratio4.27
Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Options analytics

Account required
Put / call volume
Put / call open interest
Positioning, not flow
Max pain
ATM implied vol
Nearest strike to spot
Skew (10% OTM)
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
Heaviest put OI

Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.

Free account required

Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.

Earnings

History & consensus estimates
Forward consensus
PeriodEPSAnalystsRevenueGrowth
Current quarter $247.03M +52.8%
Next quarter $267.86M +39.1%
Current year $960.15M +55.8%
Next year $1.32B +37.3%

Analyst targets & ownership

Account required
Mean target
High target
Low target
Implied upside
Analyst count
ConsensusNONE
Strong buy / Buy— / —
Hold
Sell / Strong sell— / —
Held by insiders7.47%
Held by institutions74.15%
Institutions holding547
Free account required

Price targets, consensus spread, insider and institutional ownership.

Moving averages & technicals

Computed from 2Y daily closes
SMA 10
SMA 20
SMA 50
SMA 100
SMA 200
EMA 12
EMA 26
EMA 50
RSI (14)
MACD (12,26,9)
Hist —
ATR (14)
Realised vol 30D
Annualised
Bollinger upper
20, 2σ
Bollinger lower
20, 2σ
50 / 200 cross
Trend bias

Options chain

Account required
Expiry
Spot 56.70
Calls
StrikeLastBidAskVolOIIV
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
Puts
StrikeLastBidAskVolOIIV
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Risk profile

Daily returns · 1Y window
Beta vs SPY
Correlation to SPY
Realised vol 30D
Annualised
Market vol 1Y
SPY, annualised
Max drawdown 1Y
Peak to trough
Max drawdown 5Y
Peak to trough
ATR 14
Average true range
Beta (reported)
1.67
5Y monthly, from filing

Rating changes

97 on file
DateFirm ActionFromTo
Aug 7, 26 JP Morgan MAINTAINED Overweight Overweight
Jul 27, 26 B. Riley Securities MAINTAINED Buy Buy
Jul 13, 26 HC Wainwright & Co. MAINTAINED Buy Buy
Jul 7, 26 B of A Securities MAINTAINED Underperform Underperform
Jul 6, 26 HC Wainwright & Co. MAINTAINED Buy Buy
May 27, 26 HC Wainwright & Co. MAINTAINED Buy Buy
May 6, 26 HC Wainwright & Co. MAINTAINED Buy Buy
Feb 2, 26 JP Morgan MAINTAINED Overweight Overweight
Jan 15, 26 Goldman Sachs MAINTAINED Neutral Neutral
Nov 3, 25 JP Morgan MAINTAINED Overweight Overweight
Sep 17, 25 B. Riley Securities MAINTAINED Buy Buy
Mar 4, 25 HC Wainwright & Co. MAINTAINED Buy Buy

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.